Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 4/20 | 0.42 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | RRM1 | P23921 | 1/20 | 0.33 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | S100A4 | P26447 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20872675 | 0.85 | MAOB (0.40) | TRPV4SLC1A5MAOBMAOACHEK1 | |
| SCHEMBL16034697 | 0.81 | PIK3CD (0.40) | MAOBMAOACHEK1CHRM2CHRM1 | |
| SCHEMBL19682467 | 0.79 | TRPV4 (0.49) | TRPV4MAOBMAOAMCL1ALDH1A1 | |
| SCHEMBL7765655 | 0.79 | TRPV4 (0.60) | TRPV4SLC22A12 | |
| SCHEMBL29948948 | 0.78 | TRPV4 (0.46) | TRPV4SLC22A12 | |
| SCHEMBL16080223 | 0.78 | TRPV4 (0.46) | TRPV4SLC22A12 | |
| SCHEMBL19682468 | 0.78 | TRPV4 (0.43) | TRPV4MCL1ALDH1A1HTTGAA | |
| SCHEMBL1684373 | 0.77 | ALDH1A1 (0.60) | MAOBMAOACHRM2CHRM1RRM1 | |
| SCHEMBL21171941 | 0.75 | TRPV4 (0.41) | TRPV4ALDH1A1HTTSLC22A12 | |
| SCHEMBL15565842 | 0.75 | SMN1; SMN2 (0.40) | CHRM2CHRM1RRM1RRM2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102161-A1 | METHODS OF TREATING OVARIAN AND PANCREATIC CANCER | CONCARLO THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4712963-A2 | SMALL MOLECULE INHIBITORS OF P27 | Concarlo Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250223270-A1 | Sulfonamide Compounds and Use Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-07-10 | — | — | US | disclosed |
| US-12344588-B2 | Sulfonamide compounds and use thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-07-01 | — | — | US | disclosed |
| WO-2024238709-A2 | SMALL MOLECULE INHIBITORS OF P27 | CONCARLO THERAPEUTICS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-20240190821-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF | TRIANA BIOMEDICINES INC (US) | 2024-06-13 | — | — | US | disclosed |
| CN-111386260-B | Sulfonamide compounds and uses thereof | 大鹏药品工业株式会社 | 2024-04-30 | — | — | CN | disclosed |
| EP-3466934-B1 | SULFONAMIDE COMPOUNDS OR SALT THEREOF AS RIBONUCLEOTIDE REDUCTASE INHIBITORS FOR TREATING CANCER | TAIHO PHARMACEUTICAL CO LTD (JP) | 2024-03-27 | — | — | EP | disclosed |
| EP-3717462-B1 | CO-CRYSTAL OF BENZOIC ACID AND SULFONAMIDE COMPOUND FOR THE TREATMENT OF TUMORS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2024-01-03 | — | — | EP | disclosed |
| US-11634395-B2 | Sulfonamide compound or salt thereof | Taiho Pharmaceutial Co., Ltd. (JP) | 2023-04-25 | — | — | US | disclosed |
| US-8124610-B2 | Sodium channel inhibitors | ICAGEN INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2173743-A2 | SODIUM CHANNEL INHIBITORS | Icagen, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN (US) | 2009-01-22 | — | — | US | disclosed |
| WO-2009012242-A2 | SODIUM CHANNEL INHIBITORS | ICAGEN, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| EP-1335722-B1 | INDOLYL-SULFONYL- COMPOUNDS USEFUL IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2006-08-30 | — | — | EP | disclosed |
| US-20050176705-A1 | Compounds useful in the treatment of cns disorders | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-08-11 | — | — | US | disclosed |
| EP-1335722-A2 | COMPOUNDS USEFUL IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002041889-A2 | INDOLSULFONYL COMPOUNDS USEFUL IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | TRPV1, SCN1A, SCN2A | TRPV4 23/4885SLC1A5 291/4885MAOB 2667/4885 |
| US-20050176705-A1 | Compounds useful in the treatment of cns disorders | SLC18A2, CNR2, TPH2 | TRPV4 951/4885SLC1A5 452/4885MAOB 19/4885 |
| US-20240190821-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF | PACSIN2, TPX2, PRSS12 | TRPV4 4498/4885SLC1A5 2040/4885MAOB 2059/4885 |
| US-20250223270-A1 | Sulfonamide Compounds and Use Thereof | STS, SULT2A1, TPST2 | TRPV4 1822/4885SLC1A5 1615/4885MAOB 2857/4885 |
| US-12344588-B2 | Sulfonamide compounds and use thereof | STS, SULT2A1, TPST2 | TRPV4 1822/4885SLC1A5 1615/4885MAOB 2857/4885 |
| US-11634395-B2 | Sulfonamide compound or salt thereof | RNASEH1, SNRPA1, RRM2 | TRPV4 1831/4885SLC1A5 2164/4885MAOB 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.